Diplopia After COVID-19: A Cautious Neuro-Ophthalmic Perspective
New-onset diplopia is neurological until proven otherwise — and fatigue-related diplopia still deserves respect.
As understanding of post-COVID syndromes matures, clinicians increasingly encounter neurological symptoms extending beyond fatigue and cognitive dysfunction. Visual complaints are common, but most are non-specific. Diplopia is less frequent, yet it warrants careful attention because it usually indicates disturbance of ocular alignment or ocular motor control rather than primary ocular surface disease.
The published evidence to date supports a cautious position: ocular motor palsies and diplopia have been reported following SARS-CoV-2 infection, chiefly in acute and subacute settings, and their prevalence and natural history within clearly defined Long Covid cohorts remain incompletely characterised. Early in the pandemic, Neurology reports described COVID-19 presenting with ophthalmoparesis attributable to cranial nerve palsy. Subsequent literature has continued to document oculomotor, trochlear, and abducens nerve palsies temporally associated with COVID-19 infection.
Beyond discrete cranial nerve palsies, a separate strand of evidence concerns oculomotor control in post-COVID condition (PCC). Objective eye-tracking studies in PCC, particularly among individuals with cognitive complaints, have reported alterations across saccades, pursuit, fixation, vergence, and pupillary parameters. Other cohorts have reported vision-related symptoms and measurable oculomotor findings in non-hospitalised post-COVID populations. These studies support the broader proposition that ocular motor function may be affected in some PCC patients. However, it remains premature to claim that specific syndromes such as convergence insufficiency are common without stronger prevalence data.
A small but important differential is myasthenia gravis (MG). New-onset MG has been reported after SARS-CoV-2 infection, sometimes beginning with oculo-bulbar symptoms including diplopia and ptosis. While myasthenia gravis is unlikely to explain most post-COVID visual complaints, its consequences are significant enough that fluctuating diplopia or fatigable ptosis should trigger appropriate evaluation and referral.
For generalists, the practical message remains one of measured vigilance. New-onset diplopia requires structured assessment and urgent triage where red flags are present. Where investigations are unrevealing and symptoms are stable, a post-infectious mechanism may be considered---but only after exclusion of time-critical pathology.
In summary, the evidence supports that diplopia and ocular motor dysfunction can occur after SARS-CoV-2 infection, and objective studies suggest oculomotor control changes in some PCC patients. What remains uncertain is how often diplopia forms part of Long Covid, which patients are at risk, and which interventions best help. Until better cohort data emerge, clinical curiosity should be paired with careful follow-up.
